Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

After a recent raise, this Houston biotech company is headed to first-in-human clinical trials. Photo via stellanovatx.com

JLABS-based cancer therapies company closes $15.5M series A led by Houston bioventure

fresh funds

Houston-based Stellanova Therapeutics closed a $15.5 million series A financing this month, which will advance the company's first-in-human clinical trials for oncology and help build out its team.

Stellanova is a resident company at Johnson & Johnson's biotech incubator in the TMC (JLABS @ TMC) and is one of four entities that make up cancer and disease biotech company Sporos Bioventures, which officially launched last month after closing a $38.1 million series A of its own.

Stellanova is focused on advancing therapies for cancers that are resistant to current treatments, like chemotherapy and immune therapies. According to a release, it has seen unprecedented anti-tumor activity in preclinical models of pancreas and triple negative breast cancer through the use of its lead antibody, which targets DKK3, a factor secreted by cancer-associated fibroblasts that spur tumors.

The company was founded based on research out of Dr. Rosa Hwang's lab at Houston's MD Anderson Cancer Center.

"We are thrilled to bring Stellanova into the Sporos group of companies. Stellanova means 'new star,' and it is clear the Stellanova team embraces this namesake with their entirely new approach to treating cancer," Harold Levy, Stellanova and Sporos founder and board member said in the statement. "We have been impressed by Stellanova's accomplishments and look forward to being involved in the advancement of the company's platform, one that we believe has the potential to directly combat the most devastating of cancers."

In conjunction with the financing, Stellanova also announced that it has named JLABS @ TMC founding team member Emmanuelle Schuler as the company's inaugural CEO.

Stellanova joins Sporos's Tvardi Therapeutics as it moves toward clinical trials. Tvardi, named a "most promising" by BioHouston and the Rice Alliance in December, is in Phase 1 clinical trial of its STAT3 oral inhibitor for treatment of cancer, inflammation and fibrosis.

Asylia Therapeutics and Nirogy Therapeutics were also founding entities of Sporos. The companies are in the proof of concept and discovery phases and focus on cancer, autoimmune diseases, infectious diseases, and inflammatory diseases.

A Houston biotech company has raised $38.1 million. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Houston-based cancer and disease bio-venture launches after $38.1M series A

money moves

Sporos Bioventures LLC launched this month after closing a $38.1 million round of series A financing.

The Houston-based biotech company aims to accelerate the development of breakthrough therapies for cancer and immune diseases by sharing resources, capital, access to clinical trial infrastructure, and talent from within its knowledgeable team of biotech executives, entrepreneurs, academic scholars, and investors. The company was launched with four entities: Tvardi Therapeutics, Asylia Therapeutics, Nirogy Therapeutics, and Stellanova Therapeutics.

The most advanced of the four entities, Tvardi, is currently in Phase 1 clinical trial to evaluate it's STAT3 oral inhibitor. It was named a "most promising" life sciences company at the 2020 Texas Life Science Forum, hosted by BioHouston and the Rice Alliance in December. The remaining entities are in the development stages and are focused on cancer, autoimmune disease, fibrosis, and tumor growth, among other conditions.

"Sporos was founded to accelerate the development of new medicines by addressing inefficiencies and risk in the establishment of new biotech companies," Peter Feinberg, Sporos co-founder, said in a statement. "By leveraging our extensive network, including the Texas Medical Center, we first identify transformative scientific opportunities and then deploy our top-tier talent, funding, and operational support to drive these insights into a growing pipeline of first-in-class treatment options."

In conjunction with the launch, Sporos named Michael Wyzga as the company's founding CFO. Wyzga was previously CFO at Genzyme for 12 years and has held various senior-level positions in the industry.

"By strategically deploying valuable resources to young companies that would not typically be supported by top-tier seasoned talent and infrastructure, we believe that we can efficiently bring a diverse set of therapies through clinical development," Wyzga said in a statement. "I am thrilled to join a team with decades of scientific and operational expertise and look forward to guiding our strategic and financial growth."

Wyzga joins a team of seasoned leaders in the biotech and cancer research fields, including Dr. Ronald DePinho, professor of Cancer Biology and past president of MD Anderson, who will serve as the chair of Sporos' Strategic Advisory Council. Jeno Gyuris, a biotech executive in oncology drug discovery and development with more than 25 years of experience, will serve as chief science officer. And Alex Cranberg, an experienced active early-stage biotech investor, serves as director.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Impact-driven Houston fintech startup emerges to streamline international remittance

money transfer tech

Africans living abroad send over $40 billion back to their home country annually — yet the process continues to be expensive, fraud-ridden, and complicated. A new Houston-area startup has a solution.

AiDEMONEY, based in Katy, has launched a money transfer app for mobile devices. The app enables digital transfers from the United States to five African countries: Cameroon, Ethiopia, Ghana, Kenya, and Nigeria

"International remittance has always been about people living in diaspora wanting to share their success with people back home," says Uzoma Eze, AiDEMONEY co-founder and CEO, in a news release. "By replacing profit as the point of the spear, we're helping Africans fund Africa and, ultimately, rewriting our motherland's story."

Eze co-founded the company with Felix Akompi, a fellow member of Houston's African diaspora community and the company's COO

The app, which is already available on the App Store and Google Play, focuses on blockchain-powered security and instant transfers. The company also designed the platform with a "give back" model that builds a stronger Africa.

With every transaction fee, users are funding progress in Africa. A portion of customer transaction fees to nonprofits in education and literacy, women's empowerment, and healthcare. Currently, AiDEMONEY partners with the Lagos Food Bank Initiative, Shalom Sickle Cell Foundation, Sharing Smiles Initiative, and Jenny Uzo Foundation.

"We're creating a superhighway for tens of billions in USD to flow from one part of the world to another," Eze says. "When you have the right people with the right vision, that capital tills the ground—tilling out profit, social advancement and a stronger Africa."

Doing Money Remittance Better | AiDEMONEY, The African Diaspora's Money Transfer App www.youtube.com

New Pearland healthcare training center will raise the bar for nursing in Houston

Training for More

As if those in the healthcare field needed another reason to relocate to Pearland: the HCA Healthcare Center for Clinical Advancement opened its doors on July 27.

Located at the Pearland Town Center at 11200 Broadway St., building 200, the two-story, 48,400-square-foot training center houses hospital simulation labs, virtually-connected classrooms, and debriefing rooms.

The center provides ongoing education for HCA Houston Healthcare's 7,000 nurses and will help standardize training across the system's 13 Greater Houston-area hospitals, outpatient surgery centers, emergency centers, and imaging facilities.

The utilization of simulcast technology will also facilitate education and training opportunities for colleagues working in locations across the HCA Healthcare Gulf Coast Division, which includes facilities in Corpus Christi and South Texas.

"The HCA Healthcare Center for Clinical Advancement is a significant part of our strategic nursing plan to support and grow our nurses as the differentiator at our hospitals and other facilities," says Kelli Nations, chief nurse executive at HCA Houston Healthcare, one of the city's largest healthcare systems. "It certainly helps us raise the bar for nursing care in Houston."

The first floor is designated for nurse training, which can last up to 22 weeks, depending on their specialty. Additional classroom and conference room space on the second floor will serve as a hub for new-hire orientations and the system's leadership and organizational development training for up to 250 employees at a time.

"Bringing the latest teaching technologies under one roof in a new, advanced facility is a major step in preparing our nurses to provide the highest level of care," says Nations.

Additional facility features include a simulated hospital supply room, a large break room, a mother's room for employees who are nursing, and several lounge areas.

Upcoming energy conference adds innovation focus for Houston-based event

innovating energy

The World Petroleum Congress, which plans to return to in-person status in December, is adding a new wrinkle — a pitch competition — to this year's event.

On August 4, the World Petroleum Congress announced the launch this year of the Innovation Zone, which will enable energy pioneers to showcase their offerings. The 2021 World Petroleum Congress — hosted in Houston this time around — is set for December 5-9 at the George R. Brown Convention Center.

Houston-based energy giant ConocoPhillips is sponsoring the Innovation Zone.

"For more than a century, innovation has enabled our industry to keep pace with the growing demand for safe and reliable energy," Bill Bullock, executive vice president and chief financial officer of ConocoPhillips, says in a news release. He adds that the Innovation Zone will highlight "innovations that can propel our industry's purposeful journey through the energy transition and into the future."

In all, 32 startups and individuals will pitch their products or practices on the World Petroleum Congress stage. One winner will be honored with the inaugural Energy Innovator Award.

The Innovation Zone is open to energy companies, private entities, and individuals working as independent contractors. Proposals will be evaluated on seven criteria:

  • Innovation
  • Creativity
  • Potential or actual technical or business success
  • Environmental impact
  • Stakeholder impact
  • Scalability
  • Broad-based uses

Applications for the Innovation Zone are due Aug. 20. To obtain an application, visit the World Petroleum Congress website. Representatives of ConocoPhillips and the World Petroleum Congress will sift through the applications and pick 32 finalists, who will be notified in early September.

"Startups, with their innovative business models, will play a decisive role in shaping a sustainable energy future, and for participating companies, this is a good opportunity to present and forge new links with key stakeholders and investors," says Serafina Lalany, interim executive director of entrepreneurship and innovation nonprofit Houston Exponential.

Aside from ConocoPhillips, sponsors of this year's World Petroleum Congress include Chevron, Halliburton, Accenture, Hess, ExxonMobil, BP, Qatar Petroleum, Baker Hughes, and Saudi Aramco.

The 23rd World Petroleum Congress was supposed to happen last year in Houston but was shifted to 2021 due to the COVID-19 pandemic. More than 10,000 people are expected to attend this year's event. It's been estimated that the World Petroleum Congress will pump $60 million to $80 million into the Houston economy.

Staged by the World Petroleum Council, the event hasn't been held in North America since 1987, when Houston hosted it. It's known as the "Olympics" of the oil and gas sector.

The 24th World Petroleum Congress will be held in 2023 in Calgary, Canada. The event traditionally takes place every three years.